letetresgene autoleucel (GSK3377794)

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Neoplasms

Phase 1

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT02588612

GlaxoSmithKlineNeoplasms

Start: 2016-02-01End: 2020-08-10Updated: 2021-09-05

Phase 2

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

CompletedNCT02992743

GlaxoSmithKlineNeoplasms

Start: 2016-12-06End: 2022-03-22Updated: 2023-04-11

Related Papers

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma

Journal of Clinical Oncology2025-01-2112 citations

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma

Blood Advances2022-12-196 citations

600 Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression

Regular and Young Investigator Award Abstracts2022-11-011 citations

601 Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)

Regular and Young Investigator Award Abstracts2022-11-01

Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS).

Journal of Clinical Oncology2022-06-0119 citations

391 Biomarker correlates of response in patients with advanced myxoid/round cell liposarcoma (MRCLS) treated with NY-ESO-1 TCR T cells (Letetresgene autoleucel)

Regular and Young Investigator Award Abstracts2021-11-011 citations

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.

Journal of Clinical Oncology2021-05-209 citations

Pilot study of NY-ESO-1<sup>c259</sup> T cells in advanced myxoid/round cell liposarcoma.

Journal of Clinical Oncology2018-05-2018 citations

Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).

Journal of Clinical Oncology2017-05-202 citations

A pilot study of NY-ESO-1<sup>c259</sup> T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).

Journal of Clinical Oncology2017-05-202 citations

Autologous genetically engineered NY-ESO-1<sup>c259</sup>T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

Journal of Clinical Oncology2016-05-203 citations